Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from JJ.

How Stocks React To News Can Tell More About The Stock Than The News

How a stock reacts to earnings or other news can tell an investor more about the company than the news itself.

Investors Business Daily

FDA Limits Use of Johnson & Johnson's COVID-19 Vaccine to Certain Individuals - All You Should Know

The FDA said it was limiting the use of Johnson & Johnson's (NYSE:

Benzinga

AP News Digest 4 a.m.

Here are the AP’s latest coverage plans, top stories and promotable content. All times EDT. For up-to-the minute information on AP’s coverage, visit Coverage Plan at https://newsroom.ap.org.

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

US Drug Regulator Limits Use of J&J Covid Vaccine

The US said Thursday only adults who "have personal concerns" about mRNA vaccines, access issues or medical reasons for refusing them may now receive the Johnson & Johnson Covid shot, which has been linked to a rare but serious clotting condition. The vaccine, which was authorized as a single shot,…

Asharq Al-Awsat

FDA limits use of Johnson & Johnson COVID vaccine over blood clot risks, agency says

The use of Johnson and Johnson’s COVID-19 vaccine, also known as Janssen, has been limited to “certain individuals” over rare blood clot risks, the U.S. Food and Drug Administration announced Thursday, May 5.

McClatchy Washington Bureau

FDA limits Johnson & Johnson's COVID vaccine to some people due to blood clot risk

The chances of dying following after receiving the Janssen vaccine is about 1:2,000,000. But with multiple COVID-19 vaccines available, the FDA is limiting the use of the J&J vaccine.

WEKU

FDA restricts J&J's COVID-19 vaccine due to blood clot risk

U.S. regulators are strictly limiting who can receive Johnson & Johnson’s COVID-19 vaccine due to a rare but serious risk of blood clots

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Emergent BioSolutions Suspends CDMO Guidance As It Awaits Clarity On COVID-19 Vaccine Requirements

Emergent BioSolutions Inc (NYSE:EBS) reported Q1 sales of $307.5 million, down 10% Y/Y, beating the consensus of $283 million. Total product sales increased 72% to $237.1 million, while Contract development & manufacturing (CDMO) revenues declined 67% to $60.8 million. The decrease is primarily due to the company's decision to initiate maintenance and…

Benzinga

NOT REAL NEWS: A look at what didn't happen this week

Social media users shared a range of false claims this week

The Independent UK

Morning Brief: Top Financial Stories Dominating on Wednesday, April 27

Reuters Kellogg Sues British Government Over New Sugar Rules

Benzinga

Johnson & Johnson Initiates Legal Action Against Entities Selling Fake HIV Medications

Johnson & Johnson (NYSE: JNJ) has filed the latest lawsuit to combat illicit sales of drugs in the U.S., alleging that several drug distributors and pharmacies are selling counterfeit versions of its HIV drugs.

Benzinga

JNJ, McKesson, Endo Settle $275M Opioid Claims With Alabama: Reuters

Alabama reached $276 million in settlements with Johnson & Johnson (NYSE:JNJ), McKesson Corporation (NYSE:MCK), and Endo International Plc (NASDAQ:ENDP), resolving claims on the opioid addiction crisis, the state attorney general said. McKesson will pay $141 million. JNJ and Endo will pay $70.3 million and $25 million, respectively, Alabama Attorney General Steve Marshall said in a statement. The three…

Benzinga

Stock Market Gains On Housing News, Lower Oil Prices; Positive Earnings Lift Stocks

The stock market gained broadly Tuesday as housing news and lower oil prices lifted stocks, and as more earnings came in.

Investors Business Daily

Stock Market Up Nearly 1% As Earnings Pour In; These 2 Stocks Top Buy Points

The Dow Jones Industrial Average jumped 1% after two of its components reported earnings this morning.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

J&J suspends COVID-19 vaccine sales forecast

Johnson & Johnson is suspending sales forecasts for its COVID-19 vaccine only a few months after saying the shot could bring in as much as $3.5 billion this year

Investors Business Daily

Why J&J Is Shifting Its Focus From Covid Shots — And Seeing A Stock Resurgence

Johnson & Johnson slashed its 2022 guidance on Tuesday and cut its Covid vaccines outlook entirely — but JNJ stock popped at the open.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.